Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0XPKVR
ADC Name
DM002
Synonyms
DM 002; DM-002; DM002
   Click to Show/Hide
Organization
Xadcera Biopharmaceutical (Suzhou) Co., Ltd.; Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Drug Status
Phase 1
Indication
In total 5 Indication(s)
Colorectal cancer
Phase 1
Clinical Trial
Endometrial cancer
Phase 1
Clinical Trial
Ovarian cancer
Phase 1
Clinical Trial
Prostate cancer
Phase 1
Clinical Trial
Solid tumor
Phase 1
Clinical Trial
Drug-to-Antibody Ratio
4
Antibody Name
Undisclosed
Antigen Name
Receptor tyrosine-protein kinase erbB-3 (HER3); Mucin-1 (MUC1)
  Antigen Info 
Payload Name
BCPT02
  Payload Info 
Therapeutic Target
DNA topoisomerase 1 (TOP1)
  Target Info 
Conjugate Type
Undisclosed
Combination Type
BLD1102